Barclays PLC grew its holdings in Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) by 699.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 473,077 shares of the medical equipment provider’s stock after acquiring an additional 413,885 shares during the period. Barclays PLC’s holdings in Corindus Vascular Robotics were worth $2,025,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. increased its stake in Corindus Vascular Robotics by 1,164.5% during the 2nd quarter. BlackRock Inc. now owns 6,249,156 shares of the medical equipment provider’s stock worth $18,623,000 after buying an additional 5,754,940 shares during the period. Vanguard Group Inc. boosted its holdings in Corindus Vascular Robotics by 39.5% in the second quarter. Vanguard Group Inc. now owns 5,286,173 shares of the medical equipment provider’s stock valued at $15,753,000 after purchasing an additional 1,496,809 shares during the last quarter. ARP Americas LP purchased a new position in Corindus Vascular Robotics in the third quarter valued at about $5,723,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in Corindus Vascular Robotics during the 3rd quarter valued at approximately $4,010,000. Finally, Gabelli Funds LLC acquired a new stake in Corindus Vascular Robotics during the 3rd quarter valued at approximately $3,307,000.

CVRS opened at $4.27 on Friday. Corindus Vascular Robotics Inc has a 1-year low of $0.78 and a 1-year high of $4.40.

Several equities analysts have recently commented on CVRS shares. Cowen cut Corindus Vascular Robotics from an “outperform” rating to a “market perform” rating and increased their target price for the company from $4.00 to $4.28 in a research note on Thursday, August 8th. Zacks Investment Research lowered shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th.

Corindus Vascular Robotics Profile

Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures.

See Also: Why do analysts give a neutral rating?

Want to see what other hedge funds are holding CVRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS).

Institutional Ownership by Quarter for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)

Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.